Osteonecrosis of the jaw (ONJ) is a well known complication in patients treated with bisphosphonates (BPs) for skeletal metastasis and multiple myeloma (MM). Few oncologic patients under treatment with BPs and with ONJ and metastasis or MM at the same site of the jaw have been described. We report here on a 54-year old white female who was treated with intra-venous zoledronic acid for skeletal metastasis of breast cancer who developed ONJ. Because of a fracture at the site of ONJ, resection of the affected segment was performed. Although metastasis was not suspected by pre-operative image analysis, histological examination revealed syncronous osteonecrosis and breast cancer metastasis in the resected mandibular segment. This case highlights...
Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term...
There have been reports of osteonecrosis of the jaw (ONJ) in patients (pts) with metastatic bone dis...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Background: Osteonecrosis of the jaw is a well known potential complication of bisphosphonate treatm...
Abstract BACKGROUND: Osteonecrosis of the jaw is a well known potential complication of bisphosphon...
Objective. Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bis...
Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patie...
Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patie...
A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of o...
A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of o...
Patients with multiple myeloma and metastatic cancer to the bones show reduced incidence of skeletal...
The incidence of bone metastases is high among patients with advanced cancer. Bone metastases occur ...
The efficacy of bisphosphonate in controlling skeletally-related event in cancer patients without a ...
Bisphosphonates (BPs) are used to inhibit bone resorption. Recently, they have been used in cancer p...
Antiresorptive osteonecrosis of the jaws (ARONJ) is a significant and poorly understood oral complic...
Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term...
There have been reports of osteonecrosis of the jaw (ONJ) in patients (pts) with metastatic bone dis...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Background: Osteonecrosis of the jaw is a well known potential complication of bisphosphonate treatm...
Abstract BACKGROUND: Osteonecrosis of the jaw is a well known potential complication of bisphosphon...
Objective. Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bis...
Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patie...
Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patie...
A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of o...
A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of o...
Patients with multiple myeloma and metastatic cancer to the bones show reduced incidence of skeletal...
The incidence of bone metastases is high among patients with advanced cancer. Bone metastases occur ...
The efficacy of bisphosphonate in controlling skeletally-related event in cancer patients without a ...
Bisphosphonates (BPs) are used to inhibit bone resorption. Recently, they have been used in cancer p...
Antiresorptive osteonecrosis of the jaws (ARONJ) is a significant and poorly understood oral complic...
Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term...
There have been reports of osteonecrosis of the jaw (ONJ) in patients (pts) with metastatic bone dis...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...